Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY 10065, USA.
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY 10065, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
Trends Immunol. 2019 Aug;40(8):699-718. doi: 10.1016/j.it.2019.06.004. Epub 2019 Jul 10.
Dendritic cells (DCs) are fundamental for the initiation and maintenance of immune responses against malignant cells. Despite the unique potential of DCs to elicit robust anticancer immunity, the tumor microenvironment poses a variety of challenges that hinder competent DC function and consequently inhibit the development of protective immune responses. Here, we discuss recent studies uncovering new molecular pathways and metabolic programs that tumors manipulate in DCs to disturb their homeostasis and evade immune control. We also examine certain state-of-the-art strategies that seek to improve DC function and elicit antitumor responses in hosts with cancer. Understanding and modulating DC metabolism and activity within tumors might help improve the efficacy of T cell-centric immunotherapies.
树突状细胞 (DCs) 是启动和维持针对恶性细胞免疫反应的基础。尽管 DCs 具有引发强大抗癌免疫的独特潜力,但肿瘤微环境带来了各种挑战,阻碍了 DC 功能的发挥,从而抑制了保护性免疫反应的发展。在这里,我们讨论了最近的研究,这些研究揭示了肿瘤在 DC 中操纵的新分子途径和代谢程序,以扰乱其稳态并逃避免疫控制。我们还研究了某些最新的策略,这些策略旨在改善宿主癌症中 DC 的功能并引发抗肿瘤反应。了解和调节肿瘤内 DC 的代谢和活性可能有助于提高以 T 细胞为中心的免疫疗法的疗效。